VIDEO: Tarpeyo reduces proteinuria, galactose-deficient IgA1 in IgA nephropathy

ByJonathan Barratt, MBChB, PhD

Fact checked byGina Brockenbrough, MA

ORLANDO — In this video from ASN Kidney Week, Jonathan Barratt, MBChB, PhD, discusses Calliditas Therapeutics’ Tarpeyo treatment, previously known as Nefecon, for patients with IgA nephropathy.

“In this study, we took high-risk patients with IgA nephropathy, and we randomized them to receive Nefecon for 16 mg or placebo,” Barratt told Healio. “In this study, we show that the treatment with Nefecon, now known as Tarpeyo, is highly effective at reducing proteinuria at 9 months and protecting against subsequent kidney function decline.”

Additionally, Barratt and colleagues observed a reduction in galactose-deficient IgA1 (Gd-IgA1) during a period of 9 months in the NefIgArd Clinical Trial. Compared with placebo, the median Gd-IgA1 levels fell by 21.4% after 3 months of treatment, then fell 23.5% at 6 months and finally 34% at 9 months.

Published by:

Sources/Disclosures

Collapse

Source:

Barratt J, et al. SA-PO654. Presented at: ASN Kidney Week; Nov. 3-6, 2022; Orlando (hybrid meeting).

Disclosures: Barratt reports being employed by University of Leicester; performing consulting for Astellas, Alnylam, BioCryst, Calliditas, Chinook, Dimerix, Novartis, Omeros, Travere Therapeutics, Vera Therapeutics and Visterra; receiving research funding from Novartis, GlaxoSmithKline, Calliditas, Visterra, Chinook, Omeros, Galapagos, argenx and Travere Therapeutics; and being a scientific advisor or having membership on the editorial board of Kidney International, the Clinical Journal of the American Society of Nephrology, Glomerular Diseases and Clinical Science.

American Society of Nephrology Annual Meeting

Read more

VIDEO: Tarpeyo reduces proteinuria, galactose-deficient IgA1 in IgA nephropathy

Related Content